Sunshine Coast University Private Hospital | Clinical Trials
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
570 participants in 2 patient groups
Loading...
Central trial contact
First line of the email MUST contain the NCT# and Site #.; BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal